Bartoletti, M.; Pelizzari, G.; Gerratana, L.; Bortot, L.; Lombardi, D.; Nicoloso, M.; Scalone, S.; Giorda, G.; Baldassarre, G.; Sorio, R.;
et al. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int. J. Mol. Sci. 2020, 21, 3805.
https://doi.org/10.3390/ijms21113805
AMA Style
Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R,
et al. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences. 2020; 21(11):3805.
https://doi.org/10.3390/ijms21113805
Chicago/Turabian Style
Bartoletti, Michele, Giacomo Pelizzari, Lorenzo Gerratana, Lucia Bortot, Davide Lombardi, Milena Nicoloso, Simona Scalone, Giorgio Giorda, Gustavo Baldassarre, Roberto Sorio,
and et al. 2020. "Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis" International Journal of Molecular Sciences 21, no. 11: 3805.
https://doi.org/10.3390/ijms21113805
APA Style
Bartoletti, M., Pelizzari, G., Gerratana, L., Bortot, L., Lombardi, D., Nicoloso, M., Scalone, S., Giorda, G., Baldassarre, G., Sorio, R., & Puglisi, F.
(2020). Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 21(11), 3805.
https://doi.org/10.3390/ijms21113805